Xanomeline oxalate | CAS#141064-23-5 | M1/M4 Agonist

MedKoo Cat#: 526576 | Name: Xanomeline oxalate

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Xanomeline is a muscarinic acetylcholine receptor agonist with functional selectivity for M1 and M4 receptors. Xanomeline exhibits high affinity for the M1 and M4 muscarinic receptors, leading to cognitive and antipsychotic-like effects. Due to its M1 receptor agonism, it has been investigated for improving cognitive function, particularly in Alzheimer’s disease and schizophrenia. Xanomeline exhibits persistent binding to muscarinic receptors, leading to prolonged effects even after the drug is removed.

Chemical Structure

Xanomeline oxalate

CAS#141064-23-5 (oxalate)

Theoretical Analysis

MedKoo Cat#: 526576

Name: Xanomeline oxalate

CAS#: 141064-23-5 (oxalate)

Chemical Formula: C16H25N3O5S

Exact Mass: 281.1562

Molecular Weight: 371.45

Elemental Analysis: C, 51.74; H, 6.78; N, 11.31; O, 21.54; S, 8.63

Price and Availability

Size	Price	Availability
10mg	USD 350.00	2 Weeks
25mg	USD 550.00	2 Weeks
50mg	USD 950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

131986-45-3 (free base) 141064-23-5 (oxalate) 152854-19-8 (tartrate)

Synonym

LY-246708; LY246708; LY 246708; NNC-110232; NNC 110232; NNC110232; Xanomeline; Memcor; Hexyloxy-TZTP; HexyloxyTZTP. Xanomeline oxalate

IUPAC/Chemical Name

3-(hexyloxy)-4-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-thiadiazole oxalate

InChi Key

ZJOUESNWCLASJP-UHFFFAOYSA-N

InChi Code

InChI=1S/C14H23N3OS.C2H2O4/c1-3-4-5-6-10-18-14-13(15-19-16-14)12-8-7-9-17(2)11-12;3-1(4)2(5)6/h8H,3-7,9-11H2,1-2H3;(H,3,4)(H,5,6)

SMILES Code

CN1CCC=C(C2=NSN=C2OCCCCCC)C1

Appearance

White to off-white solid powder.

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 371.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Goff DC. At Last, a Nondopaminergic Agent for the Treatment of Schizophrenia: The Combination of Xanomeline and Trospium (Cobenfy). J Clin Psychopharmacol. 2025 Feb 6. doi: 10.1097/JCP.0000000000001959. Epub ahead of print. PMID: 39913270. 2: Harvey PD, Kaul I, Chataverdi S, Patel T, Claxton A, Sauder C, Saber JN, Brannan SK, Horan WP. Capturing changes in social functioning and positive affect using ecological momentary assessment during a 12-month trial of xanomeline and trospium chloride in schizophrenia. Schizophr Res. 2025 Jan 30;276:117-126. doi: 10.1016/j.schres.2025.01.019. Epub ahead of print. PMID: 39889526. 3: Kishi T, Citrome L, Sakuma K, Hamanaka S, Nishii Y, Hatano M, Furukawa O, Saito Y, Iwata N. Xanomeline-Trospium for Adults with Schizophrenia Experiencing Acute Psychosis: A Systematic Review and Meta-analysis of Safety and Tolerability Outcomes. Pharmacopsychiatry. 2025 Jan 29. doi: 10.1055/a-2506-7022. Epub ahead of print. PMID: 39880004. 4: Smith CM, Augustine MS, Dorrough J, Szabo ST, Shadaram S, Hoffman EOG, Muzyk A. Xanomeline-trospium (CobenfyTM) for Schizophrenia: A Review of the Literature. Clin Psychopharmacol Neurosci. 2025 Feb 28;23(1):2-14. doi: 10.9758/cpn.24.1253. Epub 2024 Nov 13. PMID: 39820108; PMCID: PMC11747732. 5: Fabiano N, Wong S, Zhou C, Correll CU, Højlund M, Solmi M. Efficacy, tolerability, and safety of xanomeline-trospium chloride for schizophrenia: A systematic review and meta-analysis. Eur Neuropsychopharmacol. 2024 Dec 25;92:62-73. doi: 10.1016/j.euroneuro.2024.11.013. Epub ahead of print. PMID: 39724748. 6: Syed YY. Xanomeline/Trospium Chloride: First Approval. Drugs. 2025 Jan;85(1):103-109. doi: 10.1007/s40265-024-02126-0. Epub 2024 Dec 24. PMID: 39715912. 7: Horan WP, Sauder C, Harvey PD, Ramsay IS, Yohn SE, Keefe RSE, Davis VG, Paul SM, Brannan SK. The Impact of Xanomeline and Trospium Chloride on Cognitive Impairment in Acute Schizophrenia: Replication in Pooled Data From Two Phase 3 Trials. Am J Psychiatry. 2024 Dec 11. doi: 10.1176/appi.ajp.20240076. Epub ahead of print. PMID: 39659157. 8: Menegaz de Almeida A, Moraes Tamashiro F, Cavalcanti Souza ME, Luiz Silvério II, de Almeida Souza Miranda C, Barros Andrade Í, Kreuz M, Aquino de Moraes FC, Kelly FA. Efficacy and safety of xanomeline-trospium chloride in schizophrenia: A systematic review and meta-analysis. J Psychiatr Res. 2025 Jan;181:262-272. doi: 10.1016/j.jpsychires.2024.11.047. Epub 2024 Nov 28. PMID: 39637717. 9: Mills J. A New Antipsychotic for Schizophrenia: Xanomeline and Trospium (Cobenfy). Issues Ment Health Nurs. 2024 Dec;45(12):1364-1367. doi: 10.1080/01612840.2024.2427561. Epub 2024 Nov 29. PMID: 39612363. 10: Tandon R. Finally, a non-dopaminergic antipsychotic (xanomeline-trospium) for treatment of schizophrenia: Significance and learnings. Asian J Psychiatr. 2024 Dec;102:104320. doi: 10.1016/j.ajp.2024.104320. Epub 2024 Nov 19. PMID: 39577134. 11: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. Xanomeline. 2024 Nov 15. PMID: 39626041. 12: Hasan AH, Abid MA. Cobenfy (Xanomeline-Trospium Chloride): A New Frontier in Schizophrenia Management. Cureus. 2024 Oct 9;16(10):e71131. doi: 10.7759/cureus.71131. PMID: 39525169; PMCID: PMC11548987. 13: Xanomeline/Trospium (Cobenfy) for schizophrenia. Med Lett Drugs Ther. 2024 Nov 11;66(1715):177-179. doi: 10.58347/tml.2024.1715a. PMID: 39509155. 14: Kaul I, Sawchak S, Claxton A, Sauder C, Hassman HH, Kakar R, Walling DP, Citrome L, Zhu H, Miller AC, Brannan SK. Efficacy of xanomeline and trospium chloride in schizophrenia: pooled results from three 5-week, randomized, double- blind, placebo-controlled, EMERGENT trials. Schizophrenia (Heidelb). 2024 Nov 2;10(1):102. doi: 10.1038/s41537-024-00525-6. PMID: 39488504; PMCID: PMC11531488. 15: Beninger P. Xanomeline and Trospium Chloride. Clin Ther. 2024 Nov;46(11):938-939. doi: 10.1016/j.clinthera.2024.10.001. Epub 2024 Oct 22. PMID: 39443264. 16: Azargoonjahromi A. Current Findings and Potential Mechanisms of KarXT (Xanomeline-Trospium) in Schizophrenia Treatment. Clin Drug Investig. 2024 Jul;44(7):471-493. doi: 10.1007/s40261-024-01377-9. Epub 2024 Jun 21. PMID: 38904739. 17: Sutera N. Xanomeline-Trospium in schizophrenia: A detailed review and comparison with the Institute for Clinical and Economic Review's analysis. J Manag Care Spec Pharm. 2024 Jun;30(6):629-632. doi: 10.18553/jmcp.2024.30.6.629. PMID: 38824628; PMCID: PMC11144999. 18: Vasiliu O, Budeanu B, Cătănescu MȘ. The New Horizon of Antipsychotics beyond the Classic Dopaminergic Hypothesis-The Case of the Xanomeline-Trospium Combination: A Systematic Review. Pharmaceuticals (Basel). 2024 May 9;17(5):610. doi: 10.3390/ph17050610. PMID: 38794180; PMCID: PMC11124398. 19: Kaul I, Sawchak S, Walling DP, Tamminga CA, Breier A, Zhu H, Miller AC, Paul SM, Brannan SK. Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial. JAMA Psychiatry. 2024 Aug 1;81(8):749-756. doi: 10.1001/jamapsychiatry.2024.0785. Erratum in: JAMA Psychiatry. 2024 Aug 1;81(8):846. doi: 10.1001/jamapsychiatry.2024.2002. PMID: 38691387; PMCID: PMC11063924. 20: Leber A, Ramachandra R, Ceban F, Kwan ATH, Rhee TG, Wu J, Cao B, Jawad MY, Teopiz KM, Ho R, Le GH, Ramachandra D, McIntyre RS. Efficacy, safety, and tolerability of xanomeline for schizophrenia spectrum disorders: a systematic review. Expert Opin Pharmacother. 2024 Mar;25(4):467-476. doi: 10.1080/14656566.2024.2334424. Epub 2024 Mar 27. PMID: 38515004.